|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
Zymeworks acquired by a larger entity in 2021
Zymeworks acquired by a larger entity
|
|
gptkbp:awards
|
received multiple industry awards
|
|
gptkbp:ceo
|
gptkb:Ali_Tehrani
|
|
gptkbp:clinical_trial
|
multiple ongoing clinical trials
|
|
gptkbp:collaboration
|
collaborates with academic institutions
|
|
gptkbp:employees
|
over 200 employees
|
|
gptkbp:focus
|
therapeutics
|
|
gptkbp:founded
|
gptkb:2003
|
|
gptkbp:founder
|
gptkb:Ali_Tehrani
|
|
gptkbp:funding
|
raised significant venture capital
|
|
gptkbp:headquarters
|
gptkb:Vancouver,_Canada
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zymeworks
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:instruction_set
|
diverse pipeline of drug candidates
|
|
gptkbp:investment
|
public and private investors
|
|
gptkbp:key_people
|
gptkb:Robert_H._Mc_Cauley
gptkb:Ali_Tehrani
gptkb:Gordon_Mc_Cauley
|
|
gptkbp:location
|
gptkb:Europe
gptkb:Asia
gptkb:North_America
|
|
gptkbp:mission
|
to improve patient outcomes
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co.
collaborations with pharmaceutical companies
|
|
gptkbp:product
|
Zymeworks' lead product candidate
Zymeworks' therapeutic candidates
|
|
gptkbp:research_focus
|
autoimmune diseases
cancer therapies
|
|
gptkbp:services
|
drug development
|
|
gptkbp:technology
|
gptkb:Zymeworks'_Zymeworks_2.0_platform
Zymeworks' proprietary platform
|
|
gptkbp:trade
|
ZYME
|
|
gptkbp:traded_on
|
gptkb:NYSE
TSX
|
|
gptkbp:vision
|
to be a leader in biotherapeutics
|
|
gptkbp:website
|
www.zymeworks.com
|
|
gptkbp:bfsParent
|
gptkb:biotechnology
|
|
gptkbp:bfsLayer
|
3
|